TR200002812T2 - Efervesan formülasyonları. - Google Patents

Efervesan formülasyonları.

Info

Publication number
TR200002812T2
TR200002812T2 TR2000/02812T TR200002812T TR200002812T2 TR 200002812 T2 TR200002812 T2 TR 200002812T2 TR 2000/02812 T TR2000/02812 T TR 2000/02812T TR 200002812 T TR200002812 T TR 200002812T TR 200002812 T2 TR200002812 T2 TR 200002812T2
Authority
TR
Turkey
Prior art keywords
alkali
effervescent
formulations
effervescent formulations
sensitive
Prior art date
Application number
TR2000/02812T
Other languages
English (en)
Inventor
Tritthart Wolfram
Andre Piskernig Mario
K�Lbl Gottried
Original Assignee
Asta Medica Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Aktiengesellschaft filed Critical Asta Medica Aktiengesellschaft
Publication of TR200002812T2 publication Critical patent/TR200002812T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Bulus efervesan formülasyonlari halinde, alkaliye duyarli etki maddeleri,özellikle selejilin için, oral uygulamada çabuk eriyen tatbik sekilleriyle ilgilidir, bu formülasyonlar bir alkaliye duyarli etki maddesi ve bir veya daha fazla sayida toprak alkalikarbonattan, yenebilen bir organik asitten ve/veya sitrik asitin bir alkali tuzundan olusan bir efervesan temel maddesi ve muhtemelen de farmasötik olarak kullanilabilen yardimci maddeler içerir.
TR2000/02812T 1998-03-31 1999-03-31 Efervesan formülasyonları. TR200002812T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19814257A DE19814257A1 (de) 1998-03-31 1998-03-31 Brauseformulierungen

Publications (1)

Publication Number Publication Date
TR200002812T2 true TR200002812T2 (tr) 2001-01-22

Family

ID=7863015

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02812T TR200002812T2 (tr) 1998-03-31 1999-03-31 Efervesan formülasyonları.

Country Status (29)

Country Link
US (1) US6242002B1 (tr)
EP (1) EP1067905B1 (tr)
JP (1) JP4469494B2 (tr)
KR (1) KR100607395B1 (tr)
CN (1) CN1138529C (tr)
AR (1) AR018829A1 (tr)
AT (1) ATE224703T1 (tr)
AU (1) AU753194B2 (tr)
BG (1) BG65043B1 (tr)
BR (1) BR9909266A (tr)
CA (1) CA2326502C (tr)
CZ (1) CZ300705B6 (tr)
DE (2) DE19814257A1 (tr)
DK (1) DK1067905T3 (tr)
ES (1) ES2183555T3 (tr)
HK (1) HK1036010A1 (tr)
HU (1) HU229793B1 (tr)
IL (1) IL138605A (tr)
NO (1) NO329143B1 (tr)
NZ (1) NZ506989A (tr)
PL (1) PL192049B1 (tr)
PT (1) PT1067905E (tr)
RU (1) RU2221554C2 (tr)
SK (1) SK284477B6 (tr)
TR (1) TR200002812T2 (tr)
TW (1) TW580398B (tr)
UA (1) UA66847C2 (tr)
WO (1) WO1999049842A1 (tr)
ZA (1) ZA200005133B (tr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200604B1 (en) * 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030091629A1 (en) 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
AU2004242477B2 (en) * 1999-03-26 2007-04-19 Cima Labs Inc. Sublingual buccal effervescent
AU2007203233B2 (en) * 1999-03-26 2010-02-25 Cima Labs Inc. Sublingual buccal effervescent
DK1267840T3 (da) * 2000-03-28 2009-09-07 Sandoz Ag Granulerede partikler med maskeret smag
JP4706096B2 (ja) * 2000-10-23 2011-06-22 大正製薬株式会社 不快な味を呈する塩基性薬物配合製剤
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
US20040175456A1 (en) * 2003-03-06 2004-09-09 Lauren Keilbach Tablets for feeding fish and methods of making tablets for feeding fish
US20040191298A1 (en) * 2003-03-26 2004-09-30 Fredrik Nicklasson New formulations and use thereof
TR200300510A2 (tr) * 2003-04-18 2004-11-22 Sanovel �La� Sanay� Ve T�Caret A.�. Dağılan alendronat mikropartikül formülasyonu
DE602004031462D1 (de) 2003-12-31 2011-03-31 Cima Labs Inc Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
ATE500821T1 (de) 2003-12-31 2011-03-15 Cima Labs Inc Brauseformen von opiaten zur oralen anwendung und verfahren zur verabreichung von oxycodon
US7858121B2 (en) 2003-12-31 2010-12-28 Cima Labs, Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl
US7033511B2 (en) * 2004-01-20 2006-04-25 A-Dec, Inc. Sustained water treatment in dental equipment
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
EP3216445A1 (en) * 2004-05-28 2017-09-13 Imaginot Pty Ltd. Oral therapeutic compound delivery system
JP5209966B2 (ja) * 2005-09-01 2013-06-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 崩壊性の改善された医薬組成物の製造方法
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
WO2007059591A1 (en) * 2005-11-28 2007-05-31 Imaginot Pty Ltd Oral therapeutic compound delivery system
AU2009303979A1 (en) * 2008-10-14 2010-04-22 Mcneil Ab Multi portion intra-oral dosage form and use thereof
KR101233352B1 (ko) * 2009-04-22 2013-02-25 (주)비씨월드제약 유전자 재조합 과립구-대식세포 집락 촉진인자를 함유하는 정제
EP2440210A4 (en) 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
JP6021805B2 (ja) 2011-04-18 2016-11-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
MX2014009247A (es) 2012-02-01 2014-10-14 Intercontinental Great Brands Llc Tableta para bebida baja en calorias.
CA2889866A1 (en) 2012-12-21 2014-06-26 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
JP6411379B2 (ja) 2013-05-14 2018-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー
LT3524595T (lt) 2014-08-28 2022-09-26 Eisai R&D Management Co., Ltd. Aukšto grynumo chinolino darinys ir jo gamybos būdas
RS65049B1 (sr) 2015-02-25 2024-02-29 Eisai R&D Man Co Ltd Metoda za suzbijanje gorčine derivata kinolina
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
WO2016204193A1 (ja) 2015-06-16 2016-12-22 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ 抗がん剤
CN109303334B (zh) * 2018-10-17 2021-04-13 汤臣倍健股份有限公司 一种口腔微泡腾片及其制备方法
ES2945809T3 (es) * 2019-10-02 2023-07-07 Intas Pharmaceuticals Ltd Composiciones farmacéuticas sólidas efervescentes prácticamente sin sodio
US20230242846A1 (en) * 2020-05-28 2023-08-03 Conopco, Inc., D/B/A Unilever Tablet

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678661A (en) * 1983-09-28 1987-07-07 Gerhard Gergely Effervescent composition and method of making same
DE3440288C2 (de) * 1984-11-05 1987-03-12 Gergely, Gerhard, Dr.-Ing., Wien Pharmazeutische Zubereitung mit einem Gehalt an Ibuprofen sowie Verfahren zu ihrer Herstellung
US4861800A (en) 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
GB8807504D0 (en) 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
GB8909793D0 (en) * 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
US5128145A (en) 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
HU209605B (en) 1991-04-15 1994-09-28 Chinoin Gyogyszer Es Vegyeszet Process for production of wather-free transdermal preparation
EP0592484B1 (de) 1991-07-01 1995-01-18 Gergely, Gerhard, Dr. Reaktionsdotierte brausesysteme
ATE122228T1 (de) 1991-07-01 1995-05-15 Gergely Gerhard Verfahren zur herstellung einer pharmazeutischen zubereitung mit wenigstens zwei verschiedenen wirkstoffen und verwendung einer solchen zubereitung.
EP0593807A1 (en) 1992-10-22 1994-04-27 LTS Lohmann Therapie-Systeme GmbH & Co. KG Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
MX9300110A (es) * 1992-01-13 1994-07-29 Gerhard Gergely Preparacion farmaceutica en la forma de una tableta de efervescencia o de desintegracion o de un granulado de tipo instanteneo y procedimiento para su preparacion.
DE69334237D1 (de) * 1992-06-22 2008-09-25 State Of Oregon Through Oregon Glycinrezeptorantagonisten und ihre verwendung
DE4225730C2 (de) 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
FR2698788B1 (fr) * 1992-12-09 1995-03-03 Union Pharma Scient Appl Composition pharmaceutique effervescente contenant de l'ibuprofène et son procédé de préparation.
JPH08510720A (ja) * 1993-01-27 1996-11-12 アフィマックス テクノロジーズ ナームロゼ フェンノートシャップ 経皮的薬物送り出しのための組成物及び方法
US5287394A (en) 1993-03-22 1994-02-15 Advanced Micro Devices, Inc. Fast counter with uniform delay structures
SE9301112D0 (sv) 1993-04-02 1993-04-02 Orion-Yhtymae Oy A new composition
EP0624364B1 (de) * 1993-04-15 1996-07-24 Gerhard Dr. Gergely Brausesystem mit einem alkali- und/oder metallempfindlichen, pharmazeutischen Wirkstoff, und Verfahren zur Herstellung
DE59405277D1 (de) 1993-04-20 1998-03-26 Hexal Ag Wirkstoffplaster
US5503844A (en) * 1993-05-18 1996-04-02 Mli Acquisition Corp. Ii Foam laminate transdermal patch
EP0717614B1 (de) 1993-09-09 1998-11-25 Gergely, Gerhard, Dr. Brausegranulat und verfahren zu seiner herstellung
US5831123A (en) 1993-11-12 1998-11-03 Gerhard Gergely Process for producing a granulated material
US5484608A (en) 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
GB2290965A (en) 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
US5603955A (en) 1994-07-18 1997-02-18 University Of Cincinnati Enhanced loading of solutes into polymer gels
HU223475B1 (hu) 1994-10-24 2004-07-28 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Selegilint tartalmazó liposzoma-készítmény és eljárás ennek előállítására
DE29500718U1 (de) * 1995-01-18 1995-04-06 Rau, Reinhard, 37242 Bad Sooden-Allendorf Element einer Zeltplane zum Aufbau von kohten- und jurtenähnlichen Zeltaufbauten
CN1207675A (zh) 1995-11-06 1999-02-10 萨默塞特药品有限公司 丙炔苯丙胺的经颊和舌下给药法

Also Published As

Publication number Publication date
EP1067905B1 (de) 2002-09-25
PL192049B1 (pl) 2006-08-31
PT1067905E (pt) 2003-02-28
KR100607395B1 (ko) 2006-08-02
JP4469494B2 (ja) 2010-05-26
IL138605A (en) 2005-11-20
ES2183555T3 (es) 2003-03-16
HUP0101427A3 (en) 2001-12-28
SK284477B6 (sk) 2005-04-01
NZ506989A (en) 2002-09-27
JP2002509872A (ja) 2002-04-02
TW580398B (en) 2004-03-21
AR018829A1 (es) 2001-12-12
KR20010042317A (ko) 2001-05-25
AU4029499A (en) 1999-10-18
ATE224703T1 (de) 2002-10-15
RU2221554C2 (ru) 2004-01-20
CA2326502A1 (en) 1999-10-07
AU753194B2 (en) 2002-10-10
BG65043B1 (bg) 2007-01-31
PL343260A1 (en) 2001-07-30
US6242002B1 (en) 2001-06-05
NO329143B1 (no) 2010-08-30
NO20004721L (no) 2000-09-21
DK1067905T3 (da) 2003-02-03
DE59902843D1 (de) 2002-10-31
CZ20003482A3 (en) 2001-05-16
ZA200005133B (en) 2001-02-28
CZ300705B6 (cs) 2009-07-22
NO20004721D0 (no) 2000-09-21
BG104841A (en) 2001-07-31
BR9909266A (pt) 2000-11-21
CN1295463A (zh) 2001-05-16
HUP0101427A2 (hu) 2001-08-28
SK14322000A3 (sk) 2001-07-10
UA66847C2 (uk) 2004-06-15
HK1036010A1 (en) 2001-12-21
IL138605A0 (en) 2001-10-31
HU229793B1 (en) 2014-07-28
WO1999049842A1 (de) 1999-10-07
EP1067905A1 (de) 2001-01-17
CN1138529C (zh) 2004-02-18
CA2326502C (en) 2008-08-05
DE19814257A1 (de) 1999-10-07

Similar Documents

Publication Publication Date Title
TR200002812T2 (tr) Efervesan formülasyonları.
FR11C0017I2 (fr) Utilisation de spinosad ou d'une formulation comprennant spinosad
HK1080364A1 (en) Oral pharmaceutical forms of liquid drugs having improved bioavailability
HUP0201877A2 (hu) Hal zselatint tartalmazó, gyorsan diszpergálódó dózis formák
IT8848441A0 (it) Derivato di 4h-benzopiran-4-one o suo sale, procedimento per produrlo e composizione farmaceutica che lo contiene come ingrediente attivo
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
BRPI0508798A (pt) formulação lìquida de hormÈnio de crescimento, composição farmacêutica, forma de apresentação da formulação lìquida de hormÈnio de crescimento e uso da formulação lìquida de hormÈnio de crescimento
NO20006646D0 (no) Aminosyrederivater og legemidler inneholdende de samme som aktiv bestanddel
PL346764A1 (en) New oral formulation for 5-ht4
ATE151636T1 (de) Diphosphonsäuren und deren salze enthaltende arzneimittel
BR9608392A (pt) Preparação multiparticulada de liberação controlada e forma de dosagem em tablete.
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
PT1202956E (pt) Derivados terapeuticos e/ou nuricionalmente melhorados de ingredientes activos e composicoes de administracao oral contendo o mesmo
NO20041878L (no) Karboksylsyrederivat-forbindelser og legemidler inneholdende de samme som den aktive bestanddel.
DE50208853D1 (de) Wässrige Wirkstoffzubereitungen enthaltend pflanzenextrakte und mikroverkapselte fettlösliche Wirkstoffe
RU2000113775A (ru) Препарат для профилактики и лечения эндометрита